

Management of sickle cell disease

N. A. Alli

Wits University, South Africa

Sickle cell disease (SCD) is an inherited haemoglobin disorder that is caused by a mutation in the beta globin gene. Approximately 72 million subjects worldwide are afflicted with this disorder, 55 million of whom reside in sub-Saharan Africa. Homozygous sickle cell disease is characterized by vaso-occlusive episodes and end organ damage, and carries a high mortality during early childhood in resource poor settings. Management of SCD requires a team of health care practitioners including internists, surgeons and allied health care professionals.

The sickle gene has arisen independently more than five times globally. Its high prevalence along the equatorial belt in Africa and Asia is strongly linked to the selective survival advantage conferred to the heterozygous state against malaria. This selective advantage enjoyed by sickle cell trait has led to persistence of the sickle gene despite the high mortality of the homozygous state (balanced polymorphism). The prevalence of the sickle gene in South Africa is <1%, not unexpectedly so, since South Africa falls outside the malarial belt. However, lifting of travel restrictions post the first democratic election in 1994 has led to an influx of people from other parts of Africa, paralleled by an influx of the sickle gene. Consequently, health care workers have noted a steady increase in the number of outpatient as well as admission cases of SCD, prompting a candid re-assessment of our readiness at managing the condition viz., resources, infrastructure and expertise. In addition, there are significant cost implications that could place health budgets under strain, placing a need to educate health care workers and patients, as well as create awareness among the public at large on the subject. Learning institutions, educational platforms and media are well placed to achieve this objective.

Owing to the chronic nature of the disease and challenges faced in resource limited settings, standardization of management is desirable. Management of SCD will be discussed under the following headings: 1) acute crises, 2) complications, 3) end organ damage, 4) preventive measures. The only chance of a cure is bone marrow transplantation which has its inherent risks and limitations, although gene therapy is beginning to show some promise.

Nazeer.Alli@nhls.ac.za

Study of cases of parshnishool (i.e) heel spur by using ayurvediya raktamokshan method

Ramesh Rajguru

Krupa Ayurved Health Care, India

The presentation will show a surgical invention of Raktamokshan Method. This technique has been used from last 13 years in cases of heel spur described in Ayurvedic text as Paeshnishool. Actually it is mentioned as a vital part in the text, but we do find these types in daily routine practise.

There is intense pain in the first step in the morning time.

Comparative to Allopathic surgical operation, this method is proved to be safe & effective with no complications.

According to Allopathy, injections of corticosteroids are effective in these cases but noticed that there is lot of pain while giving injections in the Heel.

The talk would present the statistics of 100 patients. In 97% patients they got complete relief after undergone Raktamokshan method.

Biography

Ramesh Rajguru has done his Bachelor of Ayurvedic Medicine and Surgery from University of Pune. He has presented paper on study of cases of planter by using Raktamoshan in National seminar on Anushalyakarma-Mumbai (2010) and in 4th World Ayurved Congress, Bengaluru (2010) and rewarded for best video presentation. He is engaged in his clinical practice at Krupa Ayurved Health Care, Gandhinagar, Bolhegaon.

drramesh12rajguru@gmail.com